Latest Information Update: 08 Feb 2005
At a glance
- Originator AlphaRx
- Class Anti-inflammatories
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 08 Feb 2005 Discontinued - Preclinical for Neuroprotection in Canada (unspecified route)
- 22 Oct 2002 Preclinical data from a media release have been added to the Neuroprotection/Inflammation pharmacodynamics section
- 08 Nov 2001 Preclinical development for Neuroprotection/Inflammation (prevention) in Canada (Unknown route)